关键词: Disease-free survival Lymphcytes in microenvironment Markers of inflammation Ratio of neutrophils to lymphocytes

来  源:   DOI:10.1016/j.clbc.2021.04.004   PDF(Sci-hub)

Abstract:
BACKGROUND: Neutrophil to lymphocyte ratio (NLR) and stromal tumor-infiltrating lymphocytes (sTILs) are correlated with triple-negative breast cancer (TNBC) patient prognosis. However, there has been insufficient research regarding the relationship between systemic and local inflammatory states in patients with TNBC, and their effects on neoadjuvant chemotherapy (NAC) efficacy.
METHODS: The clinical data of 395 patients with TNBC admitted from January 2010 to December 2018 were collected. The Pearson χ2 test was used to analyze correlations between clinical basic pathological features, NLR, sTILs, and pathological complete response (pCR). Kaplan-Meier and Cox analyses were performed to address which clinical parameters were prognostic factors of disease-free survival (DFS).
RESULTS: There was no correlation between NLR1 (baseline NLR) and sTILs (P > .05) in these patients with TNBC. Patients with TNBC with lower NLR3 (baseline NLR of patients receiving NAC) or higher sTILs scores had better pCR rates, but this failed to reach statistical significance (P > .05). Cox analysis showed that NLR1 and sTILs were independent prognostic indicators of DFS outcome in patients with TNBC (P < .01).
CONCLUSIONS: In patients with TNBC, low NLR1 and high sTILs are associated with prolonged DFS. However, the link between systemic and local inflammation markers needs further exploration.
摘要:
背景:中性粒细胞与淋巴细胞比值(NLR)和间质瘤浸润淋巴细胞(sTIL)与三阴性乳腺癌(TNBC)患者预后相关。然而,关于TNBC患者全身和局部炎症状态之间的关系的研究不足,及其对新辅助化疗(NAC)疗效的影响。
方法:收集2010年1月至2018年12月收治的395例TNBC患者的临床资料。采用Pearsonχ2检验分析临床基本病理特征之间的相关性,NLR,sTIL,病理完全缓解(pCR)。进行了Kaplan-Meier和Cox分析,以解决哪些临床参数是无病生存(DFS)的预后因素。
结果:在这些TNBC患者中,NLR1(基线NLR)和sTIL(P>.05)之间没有相关性。具有较低NLR3(接受NAC的患者的基线NLR)或较高sTILs评分的TNBC患者具有较好的pCR率,但这未能达到统计学意义(P>.05)。Cox分析显示NLR1和sTILs是TNBC患者DFS转归的独立预后指标(P<0.01)。
结论:在TNBC患者中,低NLR1和高sTIL与延长DFS相关。然而,全身和局部炎症标志物之间的联系需要进一步探索.
公众号